# Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

> **NCT03671590** · PHASE1 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 172 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** TG-1701
- **DRUG:** Umbralisib
- **BIOLOGICAL:** Ublituximab

## Key facts

- **NCT ID:** NCT03671590
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-10
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-05-21
- **Target enrollment:** 172 (ACTUAL)
- **Why stopped:** Strategic/Business Decision
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671590, "Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03671590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*